Clinical Progress

Exploring RBN-2397's R&D successes and its clinical results at the 2023 AACR

6 December 2023
4 min read

On 14 Apr 2023, the first-in-class first-in-human phase 1 trial and translational study of the mono (ADP-ribose) polymerase-7 (PARP7) inhibitor RBN-2397 was reported at the AACR Congress.

RBN-2397's R&D Progress

RBN-2397 is a small molecule drug that falls under the therapeutic area of neoplasms and respiratory diseases. It specifically targets PARP-7, a protein involved in DNA repair processes. The drug is being developed to treat various types of cancers, including squamous cell lung carcinoma, squamous non-small cell lung cancer, and solid tumors. 

According to the Patsnap Synapse, RBN-2397 has reached the highest phase of clinical trials, which is Phase 1/2. And the clinical trial areas for RBN-2397 are primarily in the United States, United Kingdom, and Israel. The key indication is Small Cell Lung Cancer.

Detailed Clinical Result of RBN-2397

The single group assignment, open-labeled clinical trial (NCT05127590) was conducted in patients with selected advanced solid tumors.

In this study, pts with solid tumors were treated with RBN-2397 at the RP2D of 200 mg BID in 3 expansion cohorts: squamous cell carcinoma of the lung (SCCL), head and neck squamous cell carcinoma (HNSCC), and hormone receptor-positive breast cancer (HR+ BC). Objectives of the expansion phase included safety, pharmacokinetics, pharmacodynamics, and antitumor activity. 

The result showed that as of 2 July 2022, 31 pts have been treated: SCCL (n=13), HNSCC (n=10), and HR+ BC (n=8). RBN-2397-related AEs (all grades >10%) included dysgeusia (42%, n=13), nausea (26%, n=8), fatigue (23%, n=7), with Grade 3 events of nausea and pleural infection (each n=1) and ALT/AST increase (n=2), and no Grade 4 events. No significant chronic toxicities were observed. The disease control rate in response-evaluable pts was 44% in SCCL (stable disease [SD] in 4/9 pts), 71% in HNSCC (RECIST partial response [PR] for 12+ months in 1/7; SD in 4/7), and 29% in HR+ BC (SD in 2/7). Analyses of paired tumor biopsies confirmed induction of adaptive immunity with ≥2-fold increases in CD8+ T cells and/or granzyme B expression in 10 (63%) of 16 pts across tumor types. Increases in immune checkpoint expression (PD-1 and LAG3 on T cells; PD-L1 on tumor cells) from 30% to 150% were observed in 3 (60%) of 5 pt tumor samples evaluated using MIBI-SCOPE, indicating the potential to prime tumors for immune checkpoint inhibitor therapy. 

It can be concluded that RBN-2397 was well tolerated at biologically active drug exposures, with preliminary antitumor activity observed. Paired tumor biopsy translational studies demonstrated the immunomodulatory mechanism of RBN-2397 and support the ongoing trial of RBN-2397 in combination with pembrolizumab (NCT05127590).

How to Easily View the Clinical Results Using Synapse Database?

If you want to know the other clinical results of popular conferences, please lick on the “Clinical Results” on the homepage of Patsnap Synapse, which provides multi-dimensional screening and filtering of drugs, indications, targets, companies, result evaluation, release date, popular conferences, etc. to help you quickly locate the data you need. 

Select the clinical meeting you are interested in, such as ESMO. In the results, you can quickly locate the data you want to view by indication, phase and drug name. 

图形用户界面, 文本, 应用程序

描述已自动生成

A single result clearly shows important information such as registration number, phase, indication, Sponsor/Collaborator, biomarker, Trial number, dosing regimen and more. 

图形用户界面, 文本, 应用程序

描述已自动生成

If you would like to view more information about this result, you can go to the result detail page by clicking on the title. 

Above the headings, we provide the original source of the outcome data. The basic information is supplemented with more information beyond the list, such as company, study. design, etc. 

In the important Outcome Measures section, we provide both list and flowchart forms, which are convenient for you to overview the comparison group information and core indicator data. 

Finally, if you need to download these results, you can conveniently check the check boxes on the left side of the list, or directly click the "Export" button to download the data for personalized analysis and file sharing.

Click on the image below to embark on a brand new journey of drug discovery!

What are the advantages of eCRF over CRF?
"What" Series
2 min read
What are the advantages of eCRF over CRF?
6 December 2023
The advantages of eCRF over CRF include:Digital format,Security,Transportation,Ease of use,Flexibility.
Read →
SpringWorks Therapeutics announced FDA approval of OGSIVEO™ (nirogacestat) as the first treatment for adult Desmoid tumor patients
Latest Hotspot
3 min read
SpringWorks Therapeutics announced FDA approval of OGSIVEO™ (nirogacestat) as the first treatment for adult Desmoid tumor patients
6 December 2023
SpringWorks Therapeutics, Inc., a biopharma company focused on severe rare diseases and cancer, has announced FDA approval for OGSIVEO™ (nirogacestat), an oral gamma secretase inhibitor, to treat progressive desmoid tumors in adults requiring systemic therapy.
Read →
What are the inclusion criteria for priority review?
Knowledge Base
2 min read
What are the inclusion criteria for priority review?
5 December 2023
The FDA's priority review process is designed to expedite the development and review of new drugs.
Read →
IO-108: A Quick Look at Its R&D Progress and Clinical Results from the 2023 AACR
IO-108: A Quick Look at Its R&D Progress and Clinical Results from the 2023 AACR
5 December 2023
On 14 Apr 2023, the first-in-human phase 1 trial of IO-108 as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors was reported at the AACR Congress.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.